Zevra Therapeutics (ZVRA) Net Cash Flow (2014 - 2026)

Zevra Therapeutics has reported Net Cash Flow for 13 years, with the latest figure at $33.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 739.22% year-over-year to $33.0 million; the trailing twelve-month figure through Mar 2026 stood at $57.6 million (up 1122.39% YoY), and the FY2025 full-year result was $28.6 million, up 394.23% from the prior year.
• Net Cash Flow for Q1 2026 stood at $33.0 million, up from $8.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $33.0 million in Q1 2026, with the low at -$28.1 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$1.0 million across 5 years, with a median of -$569000.0 in 2023.
• Annual changes were most pronounced in 2024 — Net Cash Flow sank 3577.5% — and 2025, when it surged 2633.55%.
• Zevra Therapeutics' Net Cash Flow stood at -$4.8 million in 2022, then surged by 88.1% to -$569000.0 in 2023, then slumped by 3577.5% to -$20.9 million in 2024, then soared by 139.61% to $8.3 million in 2025, then soared by 297.59% to $33.0 million in 2026.
• The last three Net Cash Flow figures came in at $33.0 million (Q1 2026), $8.3 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.